PATRONAGES - UNDER THE AUSPICES OF

Fondazione IRCCS
Istituto Nazionale dei Tumori

WITH THE UNCONDITIONAL SUPPORT OF

PLATINUM SPONSOR

GOLD SPONSOR

SILVER SPONSOR

GENERAL INFORMATION

REGISTRATION

Registration is free of charge.
You may register for IN-PERSON ACCESS
https://www.events-communication.com/event/lungcancer2026/
https://www.lungcancer-milan.com/

For information: **segreteria@events-communication.com**

CONGRESS VENUE

Aula Magna - Fondazione IRCCS Istituto Nazionale Tumori
Via Giacomo Venezian, 1 20133 Milan (Italy)

OFFICIAL LANGUAGE AND TIME

The official language is English. The official Time is Central European Time (CET), UTC +1

C.M.E. CREDITS

CME accreditation (valid for Italian participants only) for: Medical Doctor.
RES ID CME 1023-488144 CME RES credits: 4.9
Italian CME credits will be granted to those participants who attend at least 90% of scientific works, fill in the questionnaire assessment of perceived quality and duly fill in the evaluation form answering correctly 75% of the questions.

SCIENTIFIC PROVIDER AND CONGRESS ORGANIZER

Events srl
Via L. Lotto 9, 60019 Senigallia (AN)
Via Sabotino 14, 20135 Milano (MI)
www.events-communication.com



7th Edition

LUNG CANCER
COCKTAIL WITH SCIENCE
2026

DECEMBER 21st – MILAN, ITALY

SCIENTIFIC PROGRAM

10.00 Registration

10.30 Introduction and objectives
Giuseppe Lo Russo

10.40 Welcome addresses (Italian language)
Gustavo Galmozzi, *President Fondazione IRCCS INT*
Maria Teresa Montella, *General Director Fondazione IRCCS INT*
Ruggero De Maria*, *Scientific Director Fondazione IRCCS INT*
Filippo de Braud, *Former Director Dpt. of Oncology and Hemato-Oncology, Fondazione IRCCS INT*
Massimo Di Maio, *President AIOM*

1 SESSION
NSCLC EARLY AND LOCALLY ADVANCED DISEASE

Chairs: **G. Corrao, A. De Toma, G. Viscardi**

11.00 SPECIAL LECTURE
Biomarkers for early diagnosis of lung cancer
Gabriella Sozzi

11.20 Upfront Surgery: When? Lobectomy, segmentectomy, atypical resection for whom and why?
Piergiorgio Solli

11.35 Adjuvant, Neoadjuvant and Peri-operative approach, new perspectives in wt NSCLC
Tina Cascone

11.50 Not-resectable wt locally advanced disease
Andrea Riccardo Filippi

12.05 The role for Target therapies in early and locally advanced disease
Giannis Mountzios

12.20 Round Table and Questions
All

13.00 LUNCH

2 SESSION
NSCLC ONCOGENE ADDICTED ADVANCED DISEASE

Chairs: **P. Ambrosini, C. Proto, R. Romanò**

14.00 SPECIAL LECTURE
The importance of molecular tumor board in oncology. Is the lung cancer model applicable to other neoplasms?
Giancarlo Pruneri

14.20 Liquid biopsy: are we ready for use in clinical practice?
Christian Rolfo

14.35 New perspectives for EGFR mutated patients
Alessio Cortellini

14.50 Updates for BRAF, MET, HER2 positive patients
Federico Cappuzzo

15.05 Current treatment algorithms for ALK, ROS1, RET, NTRK positive patients
Shirish Gadgeel

15.20 Round Table and Questions
All

15.50 COFFEE BREAK

***Invited**

3 SESSION
NSCLC ADVANCED DISEASE: WT AND KRAS MUTATED

Chairs: **M. Brambilla, R. Ferrara, L. Mazzeo**

16.10 SPECIAL LECTURE
Reprogramming metabolism as a treatment strategy in solid tumors
Claudio Vernieri

16.30 How to improve first-line therapy for patients with wt NSCLC?
Marina Chiara Garassino

16.45 New Strategies for wt NSCLC progressive to first line treatment
Heather Wakelee

17.00 K-RAS mutated patients: a revolution is coming
Francesco Passiglia

17.15 Round Table and Questions
All

4 SESSION
A LOOK BEYOND NSCLC

Chairs: **G. Galli, M.Occhipinti, D. Signorelli**

17.40 SCLC light at the end of the tunnel?
Stephen V. Liu

17.55 Thymic Neoplasms updates
Jordi Remon Masip

18.10 Pleural Mesothelioma: state of the art
Luana Calabrò

18.25 Round Table and Questions
All

18.50 Concluding remarks
Giuseppe Lo Russo

19.00 COCKTAIL

OVERVIEW

The treatment of lung cancer is evolving rapidly. Our annual meeting provides an update on data from major national and international conferences, allowing experts and participants to discuss the latest findings, put them in context and really understand how they affect our daily practice. Participants will have the opportunity to engage with faculty members who will share their views on the main controversies surrounding the management of lung cancer. Leading experts in the treatment of lung cancer will share their ideas and knowledge with congress participants with the ultimate goal of mutual enrichment.

PRESIDENT OF THE CONFERENCE

GIUSEPPE LO RUSSO
Thoracic Unit , Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano IT

"Let's break the ice in lung cancer"



FACULTY

Paolo Ambrosini, Thoracic Unit, Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano IT

Marta Brambilla, Thoracic Unit, Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano IT

Luana Calabrò, Associate Professor of Medical Oncology at the University of Ferrara and Director of the Clinical Oncology Unit at the Ferrara University Hospital

Federico Cappuzzo, Department of Medical Oncology 2, IRCCS Istituto Nazionale Tumori Regina Elena, Rome IT

Tina Cascone, Associate Professor, Dpt. of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX USA

Giulia Corrao, Thoracic Unit, Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano IT

Alessio Cortellini, Medical Oncology, Fondazione Policlinico Universitario Campus Bio-Medico, Roma IT

Alessandro De Toma, Oncology Department, ASST Santi Paolo e Carlo, San Paolo Hospital, Milan IT

Roberto Ferrara, Thoracic Oncology, Molecular Immunology, IRCCS Ospedale San Raffaele, Milano IT

Andrea Riccardo Filippi, Associate Professor in Radiation Oncology at the University of Milan and Head of Radiotherapy, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano IT

Shirish Gadgeel, Division Head for Hematology/Oncology, Associate Director, Patient Experience and Clinical Care, Henry Ford Cancer Institute, Detroit MI USA

Giulia Galli, Oncology Unit, Department of Oncology - Comprehensive Cancer Center, Fondazione IRCCS Policlinico San Matteo, Pavia IT

Marina Chiara Garassino, Professor of Medicine and Director of Thoracic Programs in the Section of Hematology/Oncology, University of Chicago, ILL USA

Stephen V. Liu, Medical Oncologist, Associate Professor of Medicine, Director of Thoracic Oncology, Head of Developmental Therapeutics at the Lombardi Comprehensive Cancer Center of Georgetown University, Washington, DC USA

Giuseppe Lo Russo, Thoracic Unit, Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano IT

Laura Mazzeo, Thoracic Unit, Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano IT

Giannis Mountzios, Director of the 4th Oncology Dpt. and Clinical Trials Unit, Henry Dunant Hospital Center, Athens GR

Mario Occhipinti, Thoracic Unit, Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano IT

Francesco Passiglia, Dpt. of Oncology of the University of Turin, Thoracic Oncology Unit of San Luigi Hospital, Orbassano Torino, IT

Claudia Proto, Thoracic Unit, Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano IT

Giancarlo Pruneri, Director of the Postgraduate School of Pathology at University of Milan and Director of the Dpt. of Services and Advanced Diagnostics/Head of Pathological Anatomy 2, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano IT

Jordi Remon Masip, Dpt. of Cancer Medicine, Gustave Roussy Institut, Villejuif FR

Christian Rolfo, Professor of Medicine at the Ohio State University, School of Medicine/Division Director of Medical Oncology and Associate Director for Early Phase Clinical Trials, James Comprehensive Cancer Center at OSU, Columbus OH USA

Rebecca Romanò, Thoracic Unit, Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano IT

Diego Signorelli, Medical Oncology, ASST Grande Ospedale Metropolitano Niguarda, Milano IT

Piergiorgio Solli, Head of Thoracic Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano IT

Gabriella Sozzi, Head of Epigenomics and Biomarkers of Solid Tumors Unit and Head of Dpt. of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano IT

Claudio Vernieri, Breast Unit, Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano IT

Giuseppe Viscardi, Oncology Unit, Monaldi Hospital, AORN Ospedali dei Colli, Naples IT

Heather Wakelee, Professor of Oncology, Stanford University Medical Center, Stanford USA